- Home
- VEON vs NAMS Comparison
VEON vs NAMS Comparison
Compare VEON & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VEON | NAMS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United Arab Emirates | Netherlands |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | VEON | NAMS |
|---|---|---|
| Price | $53.37 | $31.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $73.25 | $46.75 |
| AVG Volume (30 Days) | 69.5K | ★ 812.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.59 | $25.64 |
| Revenue Next Year | $7.07 | $530.85 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.55 | $14.06 |
| 52 Week High | $64.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | VEON | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 42.44 |
| Support Level | $51.66 | $30.34 |
| Resistance Level | $56.05 | $37.43 |
| Average True Range (ATR) | 2.29 | 1.73 |
| MACD | -0.33 | -0.37 |
| Stochastic Oscillator | 7.13 | 29.70 |
Price Performance
Historical ComparisonAbout VEON VEON Ltd. ADS
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.